Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
Por:
Dieterich D, Rockstroh JK, Orkin C, Gutiérrez F, Klein MB, Reynes J, Shukla U, Jenkins A, Lenz O, Ouwerkerk-Mahadevan S, Peeters M, De La Rosa G, Tambuyzer L and Jessner W
Publicada:
1 dic 2014
Resumen:
Simeprevir is an oral, once-daily, hepatitis C virus (HCV) NS3/4A protease inhibitor for the treatment of chronic HCV genotype 1 infection. Human immunodeficiency virus (HIV) coinfection accelerates progression of liver disease. This uncontrolled, open-label trial explored the safety and efficacy of simeprevir in patients with HCV genotype 1/HIV type 1 (HIV-1) coinfection.
Filiaciones:
Dieterich D:
Icahn School of Medicine at Mount Sinai, New York, New York
Rockstroh JK:
Medizinische Universitätsklinik I-Immunologische Ambulanz, Bonn, Germany
Orkin C:
Royal London Hospital, United Kingdom
:
Hospital General de Elche and Universidad Miguel Hernández, Alicante, Spain
Klein MB:
McGill University Health Centre, Montreal, Canada
Reynes J:
Centre Hospitalier Universitaire Gui De Chauliac, Montpellier, France
Shukla U:
Janssen Global Services, Titusville
Jenkins A:
Janssen Research and Development, Raritan, New Jersey
Lenz O:
Janssen Infectious Diseases BVBA
Ouwerkerk-Mahadevan S:
Janssen Research and Development, Beerse, Belgium
Peeters M:
Janssen Infectious Diseases BVBA
De La Rosa G:
Janssen Global Services, Titusville
Tambuyzer L:
Janssen Infectious Diseases BVBA
Jessner W:
Janssen Infectious Diseases BVBA
Open Access
|